Singapore Institute of Advanced Medicine Holdings Ltd. (SG:9G2)
SGX:9G2
Want to see SG:9G2 full AI Analyst Report?
9G2 Stock Chart & Stats
S$0.07
S$0.00(0.00%)
At close: 4:00 PM EST
S$0.07
S$0.00(0.00%)
Day’s Range― - ―
52-Week RangeS$0.02 - S$0.09
Previous CloseN/A
Volume159.90K
Average Volume (3M)247.96K
Market Cap
S$57.88M
Enterprise ValueS$138.91M
Total Cash (Recent Filing)S$3.85M
Total Debt (Recent Filing)S$88.57M
Price to Earnings (P/E)―
Beta-0.13
Next Earnings
Nov 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding1,231,494,600
10 Day Avg. Volume138,640
30 Day Avg. Volume247,960
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.55
Price to Sales (P/S)1.94
P/FCF Ratio-2.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue ScalingA near-doubling of revenue in 2025 signals durable market demand and successful commercial expansion. Sustained top-line growth helps absorb fixed costs, supports operating leverage, and creates a pathway to profitability if combined with cost control and margin retention.
High Gross MarginA ~92% gross margin reflects structurally favorable pricing, product mix or low variable costs. Such a high gross margin provides a durable buffer; once operating expenses are managed, the company has the structural potential to translate revenue into operating profit and strong cash generation.
Improving Free Cash Flow TrendA marked improvement in free cash flow indicates operations are moving toward better cash conversion. If revenue growth and margins persist, the trend reduces reliance on external funding and supports longer-term sustainability, even though absolute FCF remains negative today.
Bears Say
Deep Operating & Net LossesVery large negative margins are a structural constraint: they erode equity returns, necessitate ongoing financing, and limit reinvestment. Until operating expenses are aligned with improved gross profits, the company cannot sustainably self-fund growth or deliver lasting profitability.
Persistent Negative Operating Cash FlowRepeated negative operating cash flow shows the core business currently consumes cash, forcing reliance on financing or dilution. This persistent cash burn creates refinancing and liquidity risk, and undermines the firm's ability to invest in growth without external capital.
Elevated & Rising LeverageElevated and volatile leverage increases financial risk and interest burden, reducing strategic flexibility. With continued losses and cash burn, higher debt raises refinancing risk and constrains the company’s ability to capitalize on growth or absorb shocks without diluting shareholders.
9G2 FAQ
What was Singapore Institute of Advanced Medicine Holdings Ltd.’s price range in the past 12 months?
Singapore Institute of Advanced Medicine Holdings Ltd. lowest share price was S$0.02 and its highest was S$0.09 in the past 12 months.
What is Singapore Institute of Advanced Medicine Holdings Ltd.’s market cap?
Singapore Institute of Advanced Medicine Holdings Ltd.’s market cap is S$57.88M.
When is Singapore Institute of Advanced Medicine Holdings Ltd.’s upcoming earnings report date?
Singapore Institute of Advanced Medicine Holdings Ltd.’s upcoming earnings report date is Nov 03, 2026 which is in 166 days.
How were Singapore Institute of Advanced Medicine Holdings Ltd.’s earnings last quarter?
Singapore Institute of Advanced Medicine Holdings Ltd. released its earnings results on May 14, 2026. The company reported -S$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -S$0.005.
Is Singapore Institute of Advanced Medicine Holdings Ltd. overvalued?
According to Wall Street analysts Singapore Institute of Advanced Medicine Holdings Ltd.’s price is currently Overvalued.
Does Singapore Institute of Advanced Medicine Holdings Ltd. pay dividends?
Singapore Institute of Advanced Medicine Holdings Ltd. does not currently pay dividends.
What is Singapore Institute of Advanced Medicine Holdings Ltd.’s EPS estimate?
Singapore Institute of Advanced Medicine Holdings Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Singapore Institute of Advanced Medicine Holdings Ltd. have?
Singapore Institute of Advanced Medicine Holdings Ltd. has 1,231,494,600 shares outstanding.
What happened to Singapore Institute of Advanced Medicine Holdings Ltd.’s price movement after its last earnings report?
Singapore Institute of Advanced Medicine Holdings Ltd. reported an EPS of -S$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6%.
Which hedge fund is a major shareholder of Singapore Institute of Advanced Medicine Holdings Ltd.?
Currently, no hedge funds are holding shares in SG:9G2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Singapore Institute of Advanced Medicine Holdings Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.69%
12-Months-Change
Fundamentals
Return on Equity
-47.62%
Trailing 12-Months
Asset Growth
-7.63%
Trailing 12-Months
Company Description
Singapore Institute of Advanced Medicine Holdings Ltd.
Singapore Institute of Advanced Medicine Holdings Ltd. operates as a holding company with interest in providing healthcare services. It offers pharmaceutical, surgical supplies and medical laboratory services. The company was founded by Djeng Shih Kien on November 24, 2011 and is headquartered in Singapore.
Singapore Institute of Advanced Medicine Holdings Ltd. (9G2) Earnings & Revenues
Technical Analysis
Raffles Medical Group
―
Thomson Medical Group Ltd.
―
HC Surgical Specialists Ltd
―
ISEC Healthcare Ltd
―
OUE Lippo Healthcare Limited
―